Health Trials

About this trial

AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.

Eligibility criteria

Qualifiers

None

Disqualifiers

Prior gene therapy treatment

Active malignancy within past 5 years

Significant active fungal or bacterial infection

History or presence of CNS lupus or other CNS disease

Trial design

Treatments tested in this trial

  • zamtocabtagene autoleucel
  • Cyclophosphamide
  • Fludarabine

Treatment groups

48 Participants
are divided into 2 treatment groups

Locations

1
Froedtert Hospital and the Medical College of Wisconsin53226, MilwaukeeWisconsin, United States

Sponsors and collaborators

Miltenyi Biomedicine GmbH

Lead sponsor

Source ClinicalTrials.gov